Skip to main content
SpringerLink
Log in

Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use

  • Original Communications
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Summary

The neurotoxins produced byClostridium botulinum are the most potent acute toxins known and are the causative agents of the neuroparalytic disease botulism. The toxins act primarily at peripheral cholinergic synapses by blocking the evoked release of the neurotransmitter acetylcholine. There are seven distinct serotypes of toxin. All are polypeptides ofM r about 150 kDa that have similar structure and pharmacological action. In their most active forms the toxins exist as dichain molecules in which a heavy (H) chain is linked by disulphide bonding to a light (L) chain. The H chain is believed to be associated with the highly specific and avid binding of toxin to the motor nerve end plates and also with the process of internalisation of the toxin. The toxic activity appears to be associated with the L chain which blockades the calcium-mediated release of acetylcholine, probably by interfering at the molecular level with the mechanisms whereby neurotransmitter-containing vesicles merge with the plasmalemma. The type A toxin is now used therapeutically to treat a variety of conditions involving involuntary muscle spasm. The therapeutic toxin is a neurotoxin-haemagglutinin complex isolated from cultures ofC. botulinum. A controlled manufacturing process has been developed for the therapeutic toxin which is specially formulated to give a freeze-dried product having good stability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arnon S (1981) Infant botulism, pathogenesis, clinical aspects and relation to crib death. In: Lewis GE Jr (ed) Biomedical aspects of botulism. Academic Press, New York, pp 331–345

    Google Scholar 

  2. Black JD, Dolly JO (1986) Interaction of125I-labelled botulinum neurotoxins with nerve terminals. J Cell Biol 103:521–534

    PubMed  Google Scholar 

  3. Das Gupta BR, Sugiyama H (1972) A common subunit structure inClostridium botulinum type A, B and E toxins. Biochem Biophys Res Commun 48:108–112

    PubMed  Google Scholar 

  4. Dolly JO, Williams RS, Black JD, Tse CK, Hambleton P, Melling J (1982) Localisation of sites for 125-I labelled neurotoxin at the murine neuromuscular junction and its binding to rat brain synaptosomes. Toxicon 20:141–148

    PubMed  Google Scholar 

  5. Dolly JO, Black JD, Williams RS, Melling J (1984) Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalisation. Nature 307:457–460

    PubMed  Google Scholar 

  6. Eisel J, Jarausch W, Goretzki K, Henschen A, Engels J, Weller U, Hudel M, Hambermann E, Neimann H (1986) Tetanus toxin: primary structure expression inE. coli and homology with botulinum toxins. EMBO J 5:2495–2502

    PubMed  Google Scholar 

  7. Fairweather NF, Lyness VA (1986) The complete neucleotide sequence of tetanus toxin. Nucleic Acids Res 14:7809–7812

    PubMed  Google Scholar 

  8. Feldman RA, Morris JG, Pollard RA (1981) Epidemiological characteristics of botulism in the United States. In: Lewis GE Jr (ed) Biomedical aspects of botulism. Academic Press, New York, pp 271–284

    Google Scholar 

  9. Gonnering RS (1988) Negative antibody response to long-term treatments of facial spasm with botulinum toxin. Am J Ophthalmol 105:313–315

    PubMed  Google Scholar 

  10. Hambleton P, Capel B, Bailey N, Heron N, Crooks A, Melling J (1981) Production, purification and toxoiding ofClostridium botulinum type A toxin. In: Lewis GE Jr (ed) Biomedical aspects of botulism. Academic Press, New York, pp 247–260

    Google Scholar 

  11. Hambleton P, Shone CC, Melling J (1987) Botulinum toxinstructure, action and clinical uses. In: Jenner P (ed) Neurotoxins and their parmacological implications. Raven Press, New York, pp 233–260

    Google Scholar 

  12. Kozaki S (1979) Interaction of type A, B and E derivative toxins with synaptosomes of rat brain. Naunyn Schmiedeberg's Arch Pharmacol 308:67–70

    Google Scholar 

  13. Melling J, Allner K (1981) The containment of microorganisms. In: Norris JR, Richmond MH (eds) Essays in applied microbiology. Wiley, New York, pp 11/1–11/32

    Google Scholar 

  14. Melling J, Hambleton P, Shone CC (1988)Clostridium botulinum toxins: nature and preparation for clinical use. Eye 2:16–23

    PubMed  Google Scholar 

  15. Molgo J, Thesleff S (1984) Studies on the mode of action of botulinum toxin type A at the frog neuromuscular junction. Brain Res 279:309–316

    Google Scholar 

  16. Murayama S, Syoto B, Oguma K, Iida H, Kubo S (1984) Comparison ofClostridium botulinum toxin types D and C1 in molecular property antigenicity and binding ability to rat brain synaptosomes. Eur J Biochem 142:487–492

    PubMed  Google Scholar 

  17. Patrinely JR, Whiting AS, Anderson RL (1988) Local side effects of botulinum toxin infections. Adv Neurol 49:493–500

    PubMed  Google Scholar 

  18. Poulain B, Wadsworth JDF, Maisey EA, Shone CC, Melling J, Tauc L, Dolly JO (1989) Inhibition of transmitter release by botulinum toxin A. Contribution of various fragments to the intoxication process. Eur J Biochem 185:197–203

    PubMed  Google Scholar 

  19. Poulain B, Wadsworth JDF, Shone CC, Mochida S, Lande S, Melling J, Dolly JO, Taue L (1989) Multiple domains of botulinum neurotoxin contribute to its inhibiton of neurotransmitter release. J Biol Chem 264:21928–21933

    PubMed  Google Scholar 

  20. Quinn N, Hallett M (1989) Dose standardisation of botulinum toxin. Lancet I:964

    Google Scholar 

  21. Report of Working Party on Leukaemia in Childhood (1986) Improvement for children with acute lymphoblastic leukaemia. Lancet I:408

    Google Scholar 

  22. Sakaguchi G, Kozaki S, Ohishi I (1984) Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JG, Jeljiaszewicz J (eds) Bacterial protein toxins. Academic Press, London, pp 433–443

    Google Scholar 

  23. Sanchez-Prieto J, Shira TS, Evans D, Ashton A, Dolly JO, Nicholls DG (1987) Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes. Eur J Biochem 165:675–681

    PubMed  Google Scholar 

  24. Scott AB (1989) Clostridial toxins as therapeutic agents. In: Simpson LL (ed) Botulinum neurotoxin and tetanus toxin. Academic Press, New York, pp 399–412

    Google Scholar 

  25. Scott AB, Rosenbaum AL, Collins CC (1973) Pharmacological weakening of extraocular muscles. Invest Ophthalmol 12:924–927

    PubMed  Google Scholar 

  26. Shone CC (1987) Clostridium botulinum neurotoxins, their structures and modes of action. In: Watson Ellis D (ed) Natural toxicants in foods. Horwood, Chichester, pp 11–57

    Google Scholar 

  27. Shone CC, Hambleton P (1989) Toxigenic clostridia. In: Minton NP, Clarke DJ (eds)Clostridia. Plenum Press, New York, pp 265–292

    Google Scholar 

  28. Shone CC, Hambleton P, Melling J (1985) Inactivation ofClostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Eur J Biochem 151:75–85

    PubMed  Google Scholar 

  29. Shone CC, Hambleton P, Melling J (1987) A 50 kDa fragment from the NH2 terminus of the heavy subuinite ofClostridium botulinum type A neurotoxin forms channels in lipid vesides. Eur J Biochem 167:175–180

    PubMed  Google Scholar 

  30. Simpson LL (1981) The origin, structural and pharmacological activity of botulinum toxin. Pharmacol Rev 33:155–188

    PubMed  Google Scholar 

  31. Thompson DE, Brehm JK, Oultram JD, Swinfield T-J, Shone CC, Atkinson T, Melling J, Minton NP (1990) The complete amino acid sequence of theClostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene. Eur J Biochem 189:73–81

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Biologics, PHLS Centre for Applied Microbiology and Research, SP4 OJG, Porten Down, Salisbury, UK

    Peter Hambleton

Authors
  1. Peter Hambleton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hambleton, P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol 239, 16–20 (1992). https://doi.org/10.1007/BF00839205

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00839205

Key words

Search

Navigation